Companies:
49,811
Total Market Cap:
139349830221547.44
Global Rank
#1884
Country Rank
#32
Market Cap
10.47 B
Price
48.34
Change (%)
0.62%
Volume
770,537
Qiagen N.V.'s latest marketcap:
10.47 B
As of 07/05/2025, Qiagen N.V.'s market capitalization has reached $10.47 B. According to our data, Qiagen N.V. is the 1884th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 10.47 B |
| Revenue (ttm) | 2 B |
| Net Income (ttm) | 93.68 M |
| Shares Out | 216.56 M |
| EPS (ttm) | 0.42 |
| Forward PE | 20.41 |
| Ex-Dividend Date | 07/02/2025 |
| Earnings Date | 07/30/2025 |
Market Cap Chart
Data Updated: 07/05/2025
Qiagen N.V.'s yearly market capitalization.
Qiagen N.V. has seen its market value grow from $1.78 B to $10.47 B since 1998, representing a total increase of 486.59% and an annual compound growth rate (CAGR) of 6.90%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $10.47 B | 6.2% | 1884 |
| 12/31/2024 | $9.97 B | 0.61% | 1720 |
| 12/29/2023 | $9.91 B | -12.73% | 1631 |
| 12/30/2022 | $11.36 B | -10.13% | 1366 |
| 12/31/2021 | $12.64 B | 3.57% | 1494 |
| 12/31/2020 | $12.2 B | 60.05% | 1363 |
| 12/31/2019 | $7.62 B | -2.34% | 1712 |
| 12/31/2018 | $7.8 B | 7.58% | 1422 |
| 12/29/2017 | $7.26 B | 11.12% | 1744 |
| 12/30/2016 | $6.53 B | 1.77% | 1516 |
Company Profile
About Qiagen N.V.
Qiagen N.V. is a leading provider of sample-to-insight solutions, transforming biological samples into molecular insights. Headquartered in Venlo, the Netherlands, the company serves customers globally in molecular diagnostics, academia, pharmaceuticals, and applied testing.
Products & Services
- Sample Technology Consumables: Includes nucleic acid stabilization and purification kits, manual and automated processing for genotyping, gene expression, and viral/bacterial analysis.
- Immune Response Consumables: Features interferon-gamma release assays for TB testing, post-transplant testing, and viral load monitoring.
- Oncology & Reproductive Health: Offers assays for prenatal testing, sexually transmitted diseases, and HPV detection.
- Research PCR Consumables: Quantitative PCR, reverse transcription, and genotyping kits for gene expression and regulation analysis.
- NGS & Bioinformatics: Provides gene panels, library prep kits, whole genome amplification, and custom genomic services.
- Instruments & Software: Includes PCR instruments, digital PCR solutions, and software-as-a-service (SaaS) offerings.
Key Highlights
- Founded in 1984, with a strong focus on innovation in molecular diagnostics.
- Comprehensive portfolio covering sample processing, analysis, and bioinformatics.
- Serves diverse markets, including healthcare, research, and applied testing.
Frequently Asked Questions
-
What is Qiagen N.V.'s (QGEN) current market cap?As of 07/05/2025, Qiagen N.V. (including the parent company, if applicable) has an estimated market capitalization of $10.47 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Qiagen N.V. (QGEN) rank globally by market cap?Qiagen N.V. global market capitalization ranking is approximately 1884 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.